WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers;
announced that its Board of Directors (the Board) had elected
Deborah Keller as its newest member. With the addition of Ms.
Keller, the Board increased in size to 11 directors.
Advisors, LLC, an advisory and consulting firm, since her
retirement as Chief Executive Officer (CEO) of Covance Drug
Development, a business segment of Laboratory Corporation of
America>Holdings, in October 2016. Prior to her appointment as
CEO in July 2015, Ms. Keller spent more than 28 years at Covance
in a number of leadership roles, including Corporate Executive
Vice President and Group President of Research and Development
Laboratories, Corporate Senior Vice President and President of
Discovery and Translational Services, and Vice President of
Analytical Services in Europe. Prior to joining Covance, Ms.
Keller began her career as an Analytical Chemist at Perrigo
Company.
arrangements for the Companys non-employee directors, which
consists of an $80,000 annual retainer and a restricted stock
unit grant of $160,000, both prorated based on Ms. Keller’s
period of service in 2017. In addition, she will be eligible to
participate in the Company’s Director Deferred Compensation
Plan. The Companys most recent proxy statement, filed with the
Securities and Exchange Commission on March 22, 2017, describes
these arrangements under the heading Director Compensation.
agreement, the form of which was included as Exhibit 10.1 to our
Current Report on Form 8-K filed on January 6, 2009.
and any other person to which she was elected as a director, and
there are and have been no transactions since the beginning of
the Companys last fiscal year, or currently proposed, between the
Company and Ms. Keller.
the appointment of Ms. Keller to the Board. A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
furnished to Item 7.01 and shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(Exchange Act), or otherwise subject to the liabilities of that
section, nor will it be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific referencing in
such filing.
|
(d)
|
Exhibits
|
|
|
|
Exhibit 99.1
|
West Pharmaceutical Services, Inc. Press Release, dated
June 1, 2017. |
|
|
|
|
|
|
|
|
About WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST)
West Pharmaceutical Services, Inc. (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems). Its Packaging Systems segment includes primary packaging components and systems for injectable drug delivery, other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Its Delivery Systems segment includes safety and administration systems, multi-component systems for drug containment and administration and various custom contract-manufacturing solutions. WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST) Recent Trading Information
WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST) closed its last trading session up +1.87 at 98.89 with 303,660 shares trading hands.